Baricitinib improves bone properties and biomechanics in patients with rheumatoid arthritis - results of the prospective interventional BARE BONE trial.
David SimonIoanna MinopoulouStephan KemenesSara BayatKoray TascilarMelek Yalcin MutluLarissa Valor-MéndezGerhard KrönkeAxel J HueberLarissa Valor-MéndezArnd KleyerPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2023)
Bone of RA patients improves with BARI therapy as shown by an increase in trabecular bone mass and an improvement of biomechanical properties.
Keyphrases
- bone mineral density
- end stage renal disease
- postmenopausal women
- soft tissue
- chronic kidney disease
- bone loss
- bone regeneration
- clinical trial
- newly diagnosed
- randomized controlled trial
- rheumatoid arthritis
- prognostic factors
- stem cells
- ejection fraction
- mesenchymal stem cells
- systemic lupus erythematosus
- bone marrow
- phase ii
- patient reported